Diquafosol

Ophthalmic
Dry eye

Eye disorders: Eye irritation, eye discharge, conjunctival hyperaemia, eye pain, eye itching, foreign body sensation in eyes, ocular discomfort, increased lacrimation, blepharitis, hyposphagma, photophobia, blurred vision, corneal epithelium disorder (e.g. keratitis superficial, corneal erosion), conjunctivitis.

This drug may cause blurred vision, if affected, do not drive or operate machinery. Remove contact lenses prior to administration and reinsert after 15 minutes.

Description:
Mechanism of Action: Diquafosol acts on the P2Y₂ receptors on the conjunctival epithelium and goblet cell membranes thereby increasing intracellular Ca ion concentration promoting water and mucin secretion.
Pharmacokinetics:
Metabolism: Rapidly metabolised to uridine-5’-monophosphate, uridine and uracil.

Source: National Center for Biotechnology Information. PubChem Database. Diquafosol, CID=148197, https://pubchem.ncbi.nlm.nih.gov/compound/Diquafosol (accessed on Jan. 21, 2020)

Store below 30°C.

Ophthalmic Lubricants

Mun Y, Kwon JW, Oh JY. Therapeutic Effects of 3% Diquafosol Ophthalmic Solution in Patients with Short Tear Film Break-up Time-type Dry Eye Disease. BMC Ophthalmology. 2018;18:237. doi: 10.1186/s12886-018-0910-3. Accessed 18/10/2019

Nam K, Kim HJ, Yoo A. Efficacy and safety of topical 3% diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials. Ophthalmic Res. 2019 Jan;61(4):188-198. doi: 10.1159/000492896. Accessed 18/10/2019. PMID: 30654362

Buckingham R (ed). Diquafosol Tetrasodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/10/2019.

Diquas 3% Solution (Santen Pharma Malaysia Sdn. Bhd.). MIMS Malaysia. http://www.mims.com/malaysia. Accessed 18/10/2019.

Diquas 3% Solution (Santen Philippines Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 18/10/2019.